Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00591305 · ClinicalTrials.gov registry record · NA

New Therapy of Laryngeal Papilloma In Children

A NA study, sponsored by Boston University.

Terminated
Registry status
NA
Development phase
1
Enrollment target

NCT00591305 is a NA study that was terminated before completion, run by Boston University. The registered enrollment target is 1 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00591305, a NA study, was terminated before completion, sponsored by Boston University.

TERMINATED
Registry status
NA
Development phase
1 participants
Enrollment target

Study Summary

This study will determine efficacy of a new and combined treatment of laryngeal recurrent respiratory papillomatosis (RRP), by using a 585 nm pulsed dye laser (PDL) and a dietary supplement, diindolylmethane (DIM). We will compare this new treatment with PDL-only, in a total of 30 children (15 of each treatment), to determine whether this combined treatment would be effective and safe in preventing the RRP recurrence. This is the first study to combine PDL technique with DIM, to develop a new, voice-preserving and long-term effective method of managing laryngeal RRP in children.

Interventions

  • DIETARY_SUPPLEMENT diindolylmethane (DIM)
  • DEVICE 585 nm pulsed dye laser

Trial Details

FieldValue
Enrollment Target 1 participants
Start Date 2007-09
Est. Completion 2011-10
Phase NA

Sponsor

Boston University

185 total trials

What the Registry Record Tells You About NCT00591305

The ClinicalTrials.gov registry entry for NCT00591305 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston University, which has 185 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 2 interventions - of which diindolylmethane (DIM) is the first listed.

NCT00591305 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00591305 about?

NCT00591305 is a clinical study titled "New Therapy of Laryngeal Papilloma In Children". This study will determine efficacy of a new and combined treatment of laryngeal recurrent respiratory papillomatosis (RRP), by using a 585 nm pulsed dye laser (PDL) and a dietary supplement, diindolylmethane (DIM). We will compare this new treatment with PDL-only, in a total of 30 children (15 of ea...

What is the current status of trial NCT00591305?

This trial is currently terminated. It is a NA study. The enrollment target is 1 participants. The study started on 2007-09. Estimated completion is 2011-10.

What interventions are being tested in trial NCT00591305?

The interventions under investigation include: diindolylmethane (DIM) (DIETARY_SUPPLEMENT), 585 nm pulsed dye laser (DEVICE).

Who is sponsoring clinical trial NCT00591305?

This trial is sponsored by Boston University, which has 185 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.